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Abstract
Osteopetrosis caused by defective acid secretion by the osteoclast, is characterized by defective bone resorption, increased
osteoclast numbers, while bone formation is normal or increased. In contrast the bones are of poor quality, despite this
uncoupling of formation from resorption. To shed light on the effect of uncoupling in adult mice with respect to bone
strength, we transplanted irradiated three-month old normal mice with hematopoietic stem cells from control or oc/oc
mice, which have defective acid secretion, and followed them for 12 to 28 weeks. Engraftment levels were assessed by flow
cytometry of peripheral blood. Serum samples were collected every six weeks for measurement of bone turnover markers.
At termination bones were collected for mCT and mechanical testing. An engraftment level of 98% was obtained. From
week 6 until termination bone resorption was significantly reduced, while the osteoclast number was increased when
comparing oc/oc to controls. Bone formation was elevated at week 6, normalized at week 12, and reduced onwards. mCT
and mechanical analyses of femurs and vertebrae showed increased bone volume and bone strength of cortical and
trabecular bone. In conclusion, these data show that attenuation of acid secretion in adult mice leads to uncoupling and
improves bone strength.
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Introduction
Bone remodeling is a continuous process that maintains calcium
homeostasis, removes old bone and mediates microfracture repair,
thereby ensuring bone quality [1]. Bone resorption is performed
by osteoclasts, after which the osteoblasts form new bone matrix,
leading to restoration of the removed bone [2]. These two
processes are normally tightly balanced, a process referred to as
coupling [3, 4]. Recent studies have indicated that the coupling of
bone formation to bone resorption is more complex than originally
thought [5, 6], and likely includes secretion of bone anabolic
factors by the osteoclasts, independent of bone resorptive activity
[2, 7].
Osteoclasts derive from hematopoietic stem cells which, in the
presence of the osteoblast-derived molecules RANKL and M-
CSF, develop into mature multinucleated bone resorbing
osteoclasts [8, 9]. The osteoclasts resorb bone by secretion of
hydrochloric acid and proteases which, in combination, dissolve
the calcified bone matrix [8, 9]. Acidification of the resorption
compartment is achieved by active proton transport mediated by
the osteoclast specific V-ATPase, while chloride is secreted by the
chloride-proton antiporter ClC-7 [10–14].
Loss of function mutations or gene knockouts in humans and
mice of these two molecules lead to different types of osteopetrosis
indicating their importance for dissolution of the inorganic bone
matrix [10, 15, 16]. These forms of osteopetrosis are characterized
by normal or even increased indices of bone formation despite the
presence of high numbers of non-resorbing osteoclasts [17-20],
indicating that bone resorption and bone formation are no longer
coupled. Despite the high bone mass, a feature of osteopetrosis is
poor bone quality, which has been speculated to be due to the
extreme suppression of bone resorption [21, 22], the failure to
resorb calcified cartilage [9], and to hyper-activity of the
osteoblasts [23].
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A recent study of ClC-7 deficient mice indicated uncoupling of
bone formation from bone resorption [24]. However, further
characterization failed to confirm these findings due to the severe
developmental phenotype, where calcified cartilage completely
occluded the marrow cavity of all long bones [25]. This illustrates
the difficulty of investigating bone phenotypes in these very young
mice.
The oc/oc mice exhibit very severe osteopetrosis due to a
mutation in the a3 subunit of the V-ATPase, and these mice die of
anemia 3–4 weeks after birth [26]. Recent studies in these mice
have shown that the osteopetrotic phenotype can be rescued by
neonatal transplantation of normal or gene-corrected hematopoi-
etic stem cells into irradiated mice, in accordance with the
hematopoietic nature of the defect [27–30].
In order to investigate the effect of osteopetrosis on bone quality
in adult mice and also shed light on the uncoupling observed in
some forms of osteopetrosis, we induced osteopetrosis in normal 3-
month old mice by transplanting them with fetal liver derived
hematopoietic stem cells from oc/oc mice or their corresponding
control littermates, and then followed them for three or six months
and characterized their bone and osteoclast phenotypes in detail.
Materials and Methods
Mice
Breeding pairs of (C57BL/6J _ C3HheB/FeJ) F1 oc/+ mice
(CD45.2) were obtained from the Jackson Laboratory (Bar
Harbor, ME) and maintained in the conventional animal facility
at the Biomedical Centre, University of Lund.
All experiments were performed according to protocols
approved by the local animal ethics committee in both Denmark
(Ra˚det for Dyreforsøg (The Animal Experiments expectorate))
registration number 2007/561-1303 and Sweden (Malmo¨/Lunds
Djurfo¨rso¨ksetiske Na¨mnd (The ethics committee for animal studies
in Malmo¨/Lund) registration number M 128-09.
Genotyping of mice
Mice were genotyped on the day of birth using DNA extracted
from the tip of the tail as described previously [27].
Harvest and isolation of fetal liver hematopoietic cells
On embryonic day 14.5, pregnant mice were killed by CO2
poisoning, and embryos were removed. Fetal livers (FLs) were
dissected out and put into PBS (Invitrogen) supplemented with 2%
FCS (Invitrogen). Single-cell suspensions were prepared by
drawing liver cells through a 23-gauge needle followed by filtering
through a 50 mm cell strainer. Individual FLs were genotyped by
lysing a cell sample and running the PCR described above. Cells
from both wild type (+/+) and oc/+ embryos were used as controls
and henceforth designated as such, as oc/+ mice are phenotyp-
ically indistinguishable from +/+ littermates.
Transplantation and follow-up
Three-month-old mice (C57BL/6J _ C3HheB/FeJ)(CD45.1)
were irradiated with 950 cGy administered from a 137Cs source.
Four hours later mice received an intravenous transplant of 26106
freshly thawed FL cells in 300 mL PBS. To avoid infection following
transplantation the animals were treated for 14 days with Baytril in
their drinking water. After transplantation the two groups of mice
were followed for 3 months. Intraperitonal injections of calcein
(20mg/kg) were given 10 and 3 days prior to sacrifice.
For the 12 week experiment a total of 10 mice were transplanted,
5 controls and 5 oc/oc, and for the 28 week experiment a total of 11
mice were transplanted, 5 controls and 6 oc/oc. Of all the mice 1
control died of the 12 week and 2 controls died of the 28 week
experiment, excluding these from the analyses. The deaths did not
appear to be related to the transplantation procedure.
At termination the bones for mCT and mechanical testing in the
12 week experiment were stored in Lilly’s fluid until analysis after
which they were transferred to 0.9% NaCl and 0.1% NaN3, while
the bones from the 28 week experiment we stored in 0.9% NaCl
and 0.1% NaN3 at all time points. A published study clearly
showed that fixation does not impact measurements of bone
strength (Fmax) in mice [31], and thus all samples were treated
equally in the mechanical test (see later).
Engraftment and lineage distribution analysis of
peripheral blood
Peripheral blood (PB) was collected in heparin (LEO Pharma,
Thornhill, ON) after tail clipping of mice, and mixed with equal
volumes of PBS containing 2% FCS. Following centrifugation, the
supernatant was poured off, erythrocytes were lysed with NH4Cl, and
the cells were washed twice with PBS containing 2% FCS.
Subsequently, cells were incubated on ice for 20 to 30 minutes with
APC-conjugated antibodies directed against B220, CD3, Gr-1, and
Mac-1 multilineage analysis) (Becton Dickinson). The cells were
suspended in 300 mL PBS containing 2% FCS followed by addition
of 1 mg/mL 7-amino-actinomycin D (7-AAD, for detection of
nonviable cells; Sigma, St Louis, MO) before analysis using a
fluorescence-activated cell sorting (FACS) Calibur Instrument
(Becton Dickinson).
Serum collection
All sera were collected by retro-orbital bleeding after overnight
fasting of the mice 6, 12, 18, 23 and 28 weeks after transplantation.
Bone Resorption by Mature Osteoclasts
Isolated spleen cells from either genotype were differentiated
into mature osteoclasts by 4 days of culture in aMEM + M-CSF
(25 ng/mL), trypsinization, and reseeding at 900,000 cells/six-well
plate, followed by 7 days of culture in aMEM containing RANKL
(100 ng/ml) and M-CSF (25 ng/ml) with media exchanged every
day as described by Neutzsky-Wulff et al. [39]. Mature osteoclasts
from either transplantation group were lifted using trypsin and cell
scraping and reseeded on cortical bone slices (see reference [39]),
at 50,000 cells/bone slice. Culture supernatants were collected and
stored at -20uC until further analysis.
Bovine cortical bone slices
Bovine cortical bone from cows of more than 3 years of age was
cut into thin slices (0.5 cm diameter) as described by Neutzsky-
Wulff et al. [39] and stored in 70% ethanol until use. Prior to
seeding of cells, bone slices were washed thoroughly in the
appropriate medium.
Measurement of TRAP Activity in Cell Culture
Supernatants
TRAP activity in cell culture medium was measured as
described previously [32]. Briefly, samples were incubated with
TRAP reaction buffer, containing p-nitrophenyl phosphate and
sodium tartrate, for 1 hour at 37uC in the dark. The reaction was
stopped with 0.3 M NaOH. Absorbance was measured in an
ELISA reader at 405 nm with 650 nm as reference.
Biochemical Markers of Bone Turnover in serum
TRAP5b activity in serum was measured by the Mouse-TRAP
assay (SD-TR103, IDS) according to the manufacturer’s protocol.
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Serum samples from individual mice were diluted in PBS to obtain
readings within the range of the kit.
Alkaline phosphatase (ALP) was measured by mixing serum
samples or controls with substrate solution (0.95 ml AMP buffer
[50 ml Milli Q water, 6.25 ml 2-amino-2-methyl-1-propanol 95%
{A65182, Sigma}, pH adjusted to 10.0, volume adjusted to 62.5
ml by addition of Milli Q water], 9.5 ml Milli Q water, 40 mg
PNPP [P5994, Sigma], 190 mL 1M MgCl2) and incubating for 20
minutes in the dark. The reaction was stopped by addition of
0.5 M NaOH. Colorimetric changes were measured at 405 nm
with 650 nm as reference using an ELISA reader.
C-terminal type I collagen fragments (CTX-I) were measured
using the RatLaps ELISA (1RTL4000; IDS Nordic A/S, Herlev,
Denmark), according to the manufacturer’s protocol.
Serum P1NP was measured using an ELISA (IDS Nordic A/S,
Cat#AC-33F1) according to the manufacturer’s instructions.
Micro-computed tomography (micro-CT) imaging
Three-dimensional reconstructions of trabecular and cortical
bone of the lumbar vertebrae and femurs were generated with a
high-resolution micro-CT system (mCT 40; Scanco Medical AG,
Bru¨ttisellen, Switzerland). The bones were mounted in a
cylindrical specimen holder to be captured in a single scan. They
were secured with synthetic foam and were completely submerged
in physiological saltwater containing 0.1% NaN3. Scans with an
isotropic resolution of 10 mm were made using a 55-kV peak-
voltage X-ray beam. Each scan projection (300 ms) was performed
four times and averaged to optimize the signal-to-noise ratio,
thereby facilitating segmentation. The computed linear attenua-
tion coefficient of the X-ray beam in each volume element (voxel)
was stored in an attenuation map and represented by a gray value
in the reconstruction. Specific volumes of interest (VOIs) were
selected. The complete vertebral trabecular bone was selected for
analysis. To analyze the femur trabecular bone, a region of 5% of
the bone length distal of the metaphysis was evaluated. Cortical
bone analysis was performed in the region between 45 and 55%
along the length of the femurs. To discriminate between bone and
background, the reconstructions were segmented using an
appropriate fixed threshold. For cortical and trabecular bone this
threshold was the grey value comparable to respectively 500 and
350 mg hydroxyapatite/cm3. Multiple cortical and trabecular
bone parameters were determined using morphometric software
supplied by the manufacturer [for trabecular bone: bone volume
fraction (BV/TV), trabecular thickness (Tb.Th), and degree of
mineralization of the bone (DMB); for cortical bone: Cortical bone
volume (Ct.BV), cortical thickness (Ct.Th), degree of mineraliza-
tion of the bone (DMB), endocortical diameter (Ec.Dm),
endocortical marrow volume (Ec.M.Vol), and periosteal diameter
(P.Dm)].
Bone Strength Measurements
Femoral Diaphysis. The femora were carefully cleaned
from muscles and soft connective tissue. The length of the left
femora was measured using an electronic caliper and the mid-
point of the femora was marked with a permanent marker pen.
The femora were placed in a testing jig for three-points bending
with their posterior surface resting on two lower supports located
6.6 mm apart, with their midpoint centered between the two lower
supports. The testing jig was then placed in an Instron materials
testing machine (model 5566, High Wycombe, UK) and load was
applied at a constant deformation rate of 2 mm/min with a rod at
the upper anterior midpoint of the femur. During compression
testing load-deformation data were recorded using Merlin (version
3.21, Instron, High Wycombe, UK), stored on an attached PC for
later analysis. After testing, the fracture line was examined to
ensure the fracture occurred perpendicular to the longitudinal axis
of the bone. Maximum load (Fmax, N) was determined from the
load-deformation data using in-house developed software.
Femoral Neck. The proximal femur (the proximal half
obtained after the three-point bending test) was mounted in a
custom-made device for standardized fixation [33]. The fixation
device holding the specimen was then placed into the material
testing machine, and a vertical load exerted by a cylinder was
applied to the top of the femoral head. The cylinder was directed
parallel to the axis of the femoral diaphysis and moved at a
constant rate of 2 mm/min until fracture of the femoral neck.
During biomechanical testing, load-deformation values were
obtained and stored on the PC for later analysis. Maximum load
(Fmax, N) was determined from the load-displacement data using
in-house developed software.
Vertebral Body. The fourth lumbar vertebral body was
dissected free from L3 and L5 and the posterior processes were
carefully removed under a dissecting microscope using a fine
electric saw and a small clipper.
The cartilaginous endplates were removed with a small scalpel
in a fashion that left parallel planes at the cranial and caudal ends
without removing excess bone, resulting in a bone specimen height
of approximately 2.8 mm. The vertebral bone specimens were
placed in the materials testing machine between two parallel plates
and compression tested at a constant velocity of 2 mm/min until
failure. During biomechanical testing, load-deformation values
were obtained and stored on the PC for later analysis. Maximum
load (Fmax, N) was determined from the load-deformation data
using in-house developed software.
Histomorphometry and staining of plastic embedded
specimens
For specimens destined for plastic embedding, the hind legs
were fixed in 3.7% formaldehyde in PBS and stored in 70%
ethanol. Tibias were embedded in methylmethacrylate in a fully
calcified state as previously described [34]. Sections of 5 mm
thickness were cut, and stained with each of the following
solutions: Toluidine blue, Safranin O/fast green, Goldner’s
trichrome, Xylenol Orange (counterstain for calcein labeled
specimens) and TRACP stain. Histomorphometry was carried
out according to standard procedures [35] in the proximal tibia
using the Osteomeasure system (OsteoMetrics Inc.). Standard
histomorphometric measurements were performed on toluidine
blue stained sections in a region 1.1 mm long commencing
370 mm from the end of the hypertrophic zone of the growth plate.
Calculations of mineral apposition rate (MAR) were based only on
measurements of doubled labeled surfaces (dLS), which were
measured in the same region.
Assessment of bone structure by histology
Humeri were decalcified in 15% EDTA and embedded in
paraffin. Cutting was done on a HM360 microtome (Micron) at a
5 mm thickness. The sections were stained with hematoxylin and
observed through an Olympus BX60 microscope using a 20x/0,40
objective polarized through filters U-ANT and U-POT. Images
were obtained with a DP71 digital camera (Olympus) using the
CellˆA software (Olympus).
Statistics
All statistical calculations were performed by Student’s two-
tailed unpaired t-test, assuming normal distribution and equal
variance, with a significance level of P,0.05 (NS: not significant;
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*:p,0.05, **:p,0.01, ***:p,0.001). Error bars indicate standard
error of the mean (SEM).
Results
Experimental setup and engraftment analysis
Figure 1 shows the experimental setups. No signs of hepato-
splenomegaly were observed in any of the experiments (data not
shown).
At week 6 the ratio of CD45.2 (donor) cells to CD45.1 (host)
cells in peripheral blood was approximately 95% in both groups
(Figure 2A), and at 12, 18, and 28 weeks an engraftment level of
approximately 98% was obtained in both groups, confirming
successful transplantation. Since oc/oc mice have altered cellular
composition of the hematopoietic compartment [36], an analysis
of the major hematopoietic lineage cells was conducted. This
showed no changes in the levels of B220+, CD3+, Mac1High/
Gr1low, and Mac1low/Gr1high cell populations between the two
groups (Figure S1).
At termination splenocytes and bone marrow cells were isolated
and cultured on cortical bone slices for 10 days to investigate
osteoclastogenesis and function. As seen in figure 2B-C bone
resorption measured by calcium release and CTX-I is significantly
reduced in spleen-derived osteoclasts from mice transplanted with
oc/oc cells when compared to osteoclasts derived from control
animals. Furthermore, measurements of the osteoclast marker
TRACP activity in the supernatants showed no changes in
osteoclast numbers, as seen in vitro for both ClC-7 and Atp6i
deficient mice (Figure 2D)[24;37]. Similar data were obtained with
bone marrow derived osteoclasts (data not shown).
Assessment of bone volume
In alignment with attenuation of bone resorption in the oc/oc
group the bone volume fraction (BV/TV) of the trabecular
compartment of vertebrae was increased by 80%, and the
trabecular thickness (Tb.Th.) by 50% at the 12 week time point,
while no change in the mineralisation degree (DMB) was observed,
when comparing to controls (Figure 3A). In the 28 week
experiment, the increases in BV/TV and Tb.Th. in the oc/oc
group were of the same magnitude as in the 12-week experiment.
With respect to DMB a 5% increase was seen in vertebrae of the
oc/oc compared to the control group after 28 weeks of
transplantation. These data were supported by bone histomor-
phometry on vertebrae showing increased bone volume, as BV/
TV, Tb.Th and Tb.N all were increased, while Tb.Sp. was
decreased in the oc/oc group compared to the control group at the
12-week time point (Figure 3B).
In the femoral cortex, an increase in bone volume (BV) of 12%
and cortical thickness of 15% was observed when comparing oc/oc
to control at 12 weeks, while after 28 weeks the increases were 25
and 30%, respectively (Figure 3C). DMB of the femoral cortex
showed a trend towards an increase, but this was not significant.
Finally, at the 28-week time point both endocortical diameter and
marrow volume were significantly reduced in the oc/oc group
compared to control, while no changes were seen at the 12-week
time point. No changes in periosteal parameters were observed at
any of the time points.
Biochemical markers of bone turnover
Serum samples were collected throughout both experiments to
investigate bone turnover markers. To combine the experiments,
and to focus on between-group differences, rather than aspects of
age, the levels of all markers were normalized to 100% at all time
points in the control groups.
As seen in Figure 4A the level of the bone resorption marker
CTX-I is significantly lower in the oc/oc group compared to the
control group at all time points, except week 28, where overall
CTX-I levels are low due to the advanced age of the mice (baseline
CTX-I 50.167.9 ng/mL, week 28 CTX-I 24.563.5 ng/mL).
The marker of osteoclast number TRACP 5b [38;39], was highly
elevated in the oc/oc group from week 12 and throughout,
compared with the control group, indicating increased osteoclast
numbers in vivo (Figure 4B), and the ratio between CTX-I and
TRACP 5b, which is used as a index for resorption per osteoclast
Figure 1. Schematic illustration of the experimental design. A) Illustration of the irradiation and transplantation setup. B) Overview of the
timeline and sample collection times from the 12 week and 28 week experiments.
doi:10.1371/journal.pone.0027482.g001
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[38], is markedly lower in the oc/oc group than the control,
further confirming that activity per osteoclast is strongly reduced
(Figure 4C). Interestingly, the bone formation markers PINP and
ALP showed increased levels in the oc/oc group compared to the
control group at week 6, while the levels returned to normal at
week 12, and at the later time points were lower in the oc/oc group
than the control group (Figure 4D&E). Finally, CTX-II levels,
which are indicative of cartilage degradation, were similar in both
groups (data not shown).
Histomorphometric analysis
Assessment of osteoclast and osteoblast numbers did not show
any differences between the two groups (Figure 5A–D) at the 12-
week time point. Furthermore, no differences in the dynamic
parameters of bone formation, BRF/BS, MAR, MS/BS, and in
osteoid volume (OV/BV) between groups were observed
(Figure 5E-H) in the 12-week experiment.
Bone strength parameters
As osteopetrosis is associated with poor bone quality and
fractures, we investigated the consequences of induction of
osteopetrosis in aged animals using mechanical testing. As for
earlier data the values in the control group at both time points
were normalized to 100% for comparative purposes. The 3-point
bending test of the femoral mid-diaphysis showed a 33% increase
in Fmax when comparing oc/oc to control at the 12-week time
point, while at the 28-week time point the difference was 55%
(Figure 6A). At the femoral neck a significant increase of 60% in
the oc/oc compared to control was seen at the 28-week time point,
while at the 12-week time point a trend towards increased strength
was seen (Figure 6B). In the vertebrae, no significant differences
were observed, although the trends followed the other mechanical
tests (Figure 6C).
Assessment of bone structure
To further understand the effects of transplantation with
the oc/oc cells, bone structure was analyzed using polarized
light microscopy. In figure 7 it is clearly shown that cortical
bone is organized in well-structured lamellae indicating that
transplantation has no detrimental effect on bone structure.
Similar findings were obtained in trabecular bone (data not
shown).
Figure 2. Engraftment analysis and in vitro bone resorption. A) Flow cytometry analysis of peripheral blood samples stained with an antibody
against CD45.2 to quantify the level of engraftment. Flow cytometry was conducted in samples from all mice (see Methods section) and at the time
points indicated. B-D) Splenocytes were isolated and cultured on bovine cortical bone in the presence of RANKL and M-CSF. At day 10 bone
resorption was measured by CTX-I (B) and calcium release (C) release and osteoclast numbers measured by TRACP activity in the supernatants (D).
Osteoclast cultures are representative of two individual experiments with 6 replicates of each condition.
doi:10.1371/journal.pone.0027482.g002
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Figure 3. Assessment of bone volume. A) mCT analysis of the vertebrae from both the 12 and the 28-week experiment. For comparison the
control group was normalized to 100%. 1) Bone volume/Total Volume (BV/TV) in % of control, 2) Trabecular Thickness (Tb.Th.) in % of control, and 3)
Degree of Mineralization of the Bone (DMB) in % of control. B) Bone histomorphometry on vertebrae from the 12-week experiment. 1) Bone volume/
Total Volume (BV/TV), 2) Trabecular Thickness (Tb.Th.), 3) Trabecular Number (Tb.N.), and 4) Trabecular Spacing (Tb.Sp.) C) mCT analysis of the femur
diaphysis from both the 12 and the 28-week experiment. For comparison the control group was normalized to 100%. 1) Cortical Bone Volume (Ct.BV)
in % of control, 2) Cortical Thickness (Ct.Th.) in % of control, 3) Cortical Degree of Mineralization of Bone (DMB) in % of control, 4) Endocortical
The Effect of Osteopetrosis in Adult Mice
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27482
Discussion
The hematopoietic nature of osteopetrosis was established in the
mid 1970s by transplantations of spleen cells from either healthy
donor mice to osteopetrotic mice, or vice versa [40, 41, 41, 42].
Transfer of oc/oc splenocytes into healthy young mice led to
increased bone weight [30], however other bone parameters were
not examined.
Here we present novel data on the establishment of osteope-
trosis in skeletally mature mice, in order to isolate the effect of non-
resorbing osteoclasts on mature bone from the influence of non-
resorbing osteoclasts on skeletal development and the resorption of
mineralized cartilage in young mice.
Using fetal liver cells as a source of hematopoietic cells [27] an
engraftment level in excess of 95% was obtained at 12 weeks, and
the levels were around 98% 28 weeks after transplantation,
confirming transplantation efficiency. No signs of hepatospleno-
megaly were observed in any of the experiments, and no
alterations in the cells of the hematopoietic lineages were observed,
in contrast to haemopoietic defects observed in mice with lifelong
osteopetrosis [10, 26, 36, 37]. This, not surprisingly, indicates that
the haemopoietic phenotype of oc/oc mice is a developmental
phenotype, in which the anemia effect is compounded by the
complete lack of bone marrow cavities in mice with osteopetrosis
due to defective acid secretion [10, 26, 36, 37]. These findings are
further supported by studies in RANKL and RANK deficient
mice, which have a less severe bone phenotype than oc/oc, Atp6i
and ClC-7 deficient mice, and accordingly have only mild changes
in the hematopoietic system and show no sign of anemia [43, 44];
however, to fully understand these differences more detailed
analyses are needed.
To validate that the osteoclasts were non-resorbing, osteoclas-
togenesis and bone resorption were evaluated using spleen and
bone marrow-derived osteoclasts from mice transplanted with
either oc/oc or control hematopoietic cells. These data confirmed
functional deficiency of the oc/oc osteoclasts, while showing no
changes in osteoclastogenesis, as expected from a previous study of
osteoclasts lacking the a3 subunit of the proton pump [37], as well
as studies of osteoclasts with defective acid secretion [10, 11, 24,
37, 45]. These data also fit well with earlier findings showing that
the increased numbers of osteoclasts in the acid secretion deficient
mice are caused by increased survival of the osteoclasts, but not by
changes in osteoclastogenesis [11, 46, 47].
In both human and murine osteopetrosis forms caused by
defective acid secretion by the osteoclasts, bone quality is low and
fractures are frequent [48-50]; however the explanation for this
has never been clear, and the possibilities include over-suppression
of bone turnover, accelerated osteoblast function, the presence of
woven, and therefore immature, bone, and finally failure to resorb
calcified cartilage [9, 21-23].
Our mechanical testing data of both trabecular and cortical
bone indicate that induction of osteopetrosis in adult animals
leads to increased bone strength. Since we found almost no
remaining calcified cartilage, as well as no changes in cartilage
Diameter (Ec.Dm.) in % of control, 5) Endocortical Marrow Volume (Ec.M.V.) in % of control, 6) Periosteal Diameter (P.Dm.) in % of control. mCT was
conducted on all bones from mice having completed the study (see methods section).
doi:10.1371/journal.pone.0027482.g003
Figure 4. Biochemical markers of bone turnover. Serum samples were collected in both experiments and CTX-I (A), TRACP 5b (B), CTX/TRACP
5b (C), ALP (D), P1NP (E) were measured at baseline and at week 6, 10, 18, 22 and 28, post transplantation. The oc/oc data (gray squares) are plotted
as percent of control (black circles) at all time points, and when samples from both experiments were present they were pooled after normalization.
The biomarker measurements were conducted in samples from all mice, and for the samples collected during the first 12 weeks on pooled data from
both experiments as described in the Methods section.
doi:10.1371/journal.pone.0027482.g004
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degradation markers, these data suggest that it is the remaining
calcified cartilage in the bones of young osteopetrotic mice that
is the basis of the poor bone strength [51]. However, the gained
bone was notably devoid of woven bone, a phenomenon
observed in classical osteopetrosis, and thus the increase in
lamellar bone volume is likely to also contribute the increased
bone strength observed in the adult osteopetrotic mice. The tests
performed do not take into account whether the bones from the
transplanted osteopetrotic mice are more brittle at the tissue
level; however, as the degree of mineralization only increases
modestly and more slowly than breaking strength, this does not
appear to be the cause. Furthermore, the normal bone structure
observed in the oc/oc groups also supports the notion that the
gained bone is normal at all levels. Importantly, these
experiments do not take into account whether the poor bone
quality observed in young oc/oc mice is due to expression of the
a3 subunit of the V-ATPase in non-hematopoietic cells, i.e.
gastric the parietal cells which are involved in calcium
homeostasis [52]; however, as the fragility of osteopetrotic bone
is common to multiple types of osteopetrosis this does not
appear to be likely. Increased bone strength has been observed
in cortical, but not vertebral bone, of cathepsin K deficient mice
[53], and in cortical bone of Ae2a,b deficient mice [54].
However, these mice also have thickened cortices, as opposed
to acid secretion deficient mice, which have very little if any
normal cortex [25]. Furthermore, the Ae2a,b and cathepsin K
deficient mice also show less dramatic accumulation of calcified
cartilage in the bone marrow cavities [54;55]. CT analysis of the
bones showed increased bone volume in both trabecular and
cortical compartments. Interestingly, the increase in bone
volume in the vertebrae appeared to plateau after only three
months, while the increase in femoral bone volume was
continuous. Furthermore, the increase in cortical bone volume
appeared to be mainly caused by a reduction in endocortical
resorption, as endocortical diameter was reduced, but periosteal
parameters were not changed.
Figure 6. Bone strength analysis. Maximal force achieved at failure (Fmax) as determined by 3-point bending test of the femoral cortex (A) or
femoral neck (B). In C Fmax was determined by vertebral compression. Bone strength testing was conducted on all bone specimens collected as
described in the methods section.
doi:10.1371/journal.pone.0027482.g006
Figure 5. Bone histomorphometry. At termination of the 12-week experiment vertebrae were collected for bone histomorphometry. No
significant differences were observed in osteoclast surface per unit bone surface (Oc.S/BS), number of osteoclasts per unit bone perimeter (N.Oc.Pm),
osteoblast surface per unit bone surface (Ob.S/BS), number of osteoblasts per unit bone perimeter (N.Ob.Pm), bone formation rate (BFR/BV), mineral
appositional rate (MAR), mineralizing surface (MS/BS) or osteoid volume (OV/BV). Bone histomorphometry was conducted on all specimens from the
12-week experiment (see Methods section).
doi:10.1371/journal.pone.0027482.g005
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The increase in bone volume is explained by the changes
observed in biochemical markers. Bone resorption CTX-I was
significantly reduced, which is as expected from the in vitro data,
and this reduction in bone resorption most likely explains most of
the increase in bone volume and bone strength. This differs from
data presented in osteopetrosis models where the defect is present
during bone development [24, 56]. However, a study conducted in
ClC-7 deficient mice, which have a phenotype closely matching
that of the oc/oc mice, indicated that the high resorption marker
levels originate from resorption of non-mineralized matrices,
which have not been removed correctly during endochondral
ossification. The reasoning being that CTX-I release occurred
completely independent of acid secretion by the osteoclast, and
thus independent of resorption of calcified bone [24, 25].
As expected from previous studies, osteoclasts numbers increase
with defective acid secretion [17, 18, 20, 46, 47, 57, 58]. In
confirmation of a large reduction in resorptive capacity per
osteoclast, the CTX-I/TRACP5b ratio was suppressed strongly
[38]. The bone formation markers PINP and ALP were both
increased by 6 weeks after transplantation, by 12 weeks they had
returned to control levels, and at the later stage both these markers
were decreased. The effect of this transient increase in bone
formation on bone volume and strength is not clear, but the lower
level of bone formation after 12 weeks may explain why the
vertebral bone volume plateaus from that time, despite the
ongoing reduction in resorption.
Taken together, the biochemical markers show that in early
stages of induced osteopetrosis, bone formation is uncoupled from
bone resorption, corresponding well to previous data from
osteoclast-rich forms of osteopetrosis caused by defective acid
secretion [17, 19, 20]. In contrast, in osteoclast-poor forms of
osteopetrosis bone formation is low from the starting point [59,
60], and in bisphosphonate or OPG-treated animals bone
formation levels decrease rapidly after onset of treatment [61].
With respect to histomorphometry, we could neither confirm an
increase in osteoclast numbers, nor a change in bone formation at
week 12; and we speculate that it may require more time to see
these differences by histomorphometry, as the early effects are
mainly driven by the reduction in resorption, while the increased
osteoclast survival is not seen until week 12 and at this time point
the effect on the osteoclast marker TRACP 5b is not very
dramatic. Furthermore, the biomarkers reflect the whole skeleton,
whereas histomorphometry reflects only the vertebrae, and thus
the markers will accumulate systemic changes. These biomarkers
have, on the other hand, been shown to clearly reflect larger
changes observed by histomorphometrical analysis [38, 61, 62].
Although bone formation decreases at later stages, these data
indicate that when acid secretion by the osteoclast is attenuated a
period of anabolic activity occurs. However, the duration and
extent of this activity will need further investigation as osteoclast-
rich osteopetrosis patients appear to have normal or increased
levels of bone formation, even though bone resorption per
osteoclast is significantly reduced [17–20].
The mechanisms controlling the coupling of bone formation to
bone resorption have long been under debate, and several recent
lines of evidence have indicated that the osteoclasts themselves,
rather than their activity, are essential for the control of bone
formation [2, 4, 17–20, 59, 60, 63–67]. In addition to the acid
secretion deficient mice and patients, studies in cathepsin K
deficient mice, and cathepsin K inhibitors in monkeys, have shown
Figure 7. Analysis of bone structure. Bone structure was assessed using polarized light microscopy as described in the methods section.
doi:10.1371/journal.pone.0027482.g007
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increased bone formation, despite reduced bone resorption,
although the effects appear to be bone type dependent [53, 68,
69]. One study showed that inhibition of cathepsin K in osteoclasts
in vitro led to augmented release of anabolic factors from the
resorption compartment, while inhibition of acid secretion by
bafilomycin prevented the release of anabolic factors [70]. All
these data strongly indicate that the osteoclasts possess the ability
to induce an anabolic response in osteoblasts. In addition,
evidence has been provided that osteoclast-derived ephrinB2
might promote bone formation by acting upon receptor EphB4 in
the osteoblast lineage, by a contact-dependent mechanism [71].
However, whether these are the factors involved in the uncoupling
seen in these mice, and to what extent the coupling molecules
originate from either bone resorption or directly from the
osteoclasts, remain to be studied.
In conclusion, we here show an increase in bone volume and
bone strength when osteopetrosis due to impaired acid seretion
from osteoclasts is induced in adult mice. This suggests that the
low bone quality seen in osteopetrosis in young animals most likely
is due to the developmental nature of the phenotype. Furthermore,
these data support that an ‘‘uncoupling’’ between bone resorption
and bone formation can be obtained when attenuating acid
secretion by the osteoclasts. Finally, the substantial increase in
bone volume and bone strength observed in otherwise healthy
mice with attenuated osteoclast acidification warrant further
investigation of the osteoclastic V-ATPase as a therapeutic target
for osteoporosis.
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